Whole Transcriptome Analysis Expands Understanding of Cancer Gene Fusions

By LabMedica International staff writers
Posted on 18 Nov 2026

Gene fusions can be clinically important alterations in oncology, but rare and novel fusion events may be difficult to identify without broad molecular profiling. This creates a diagnostic challenge across solid tumors, particularly when potentially actionable fusion partners are not captured in reference databases. Newly presented research now shows how comprehensive RNA sequencing can help detect and characterize gene fusions across large tumor datasets.

Caris Life Sciences presented two Caris-led studies using Whole Transcriptome Sequencing (WTS) and clinico-genomic data at the Association for Molecular Pathology 2026 Annual Meeting. The studies focused on fusion discovery in gynecologic serous carcinoma and a broad pan-cancer cohort. They also included WTS-based outcome analyses in non-small cell lung cancer and cholangiocarcinoma.


Image Credit: 123RF

The technology uses comprehensive RNA sequencing to detect fusion transcripts and support molecular profiling of tumor samples. In one large-scale analysis, WTS was applied to 698,406 solid tumors to investigate novel gene fusions and evaluate outcomes associated with matched therapies. In a second study, researchers characterized rare PAK-family gene fusions in ovarian, fallopian tube, and primary peritoneal serous carcinomas.

WTS detected fusion transcripts in 503,460 of 698,406 solid tumors, representing 72.1% of the cohort. More than 34,000 tumors had fusions classified as clinically significant, and more than 91% of actionable fusion pairs identified were not previously listed in the reference databases used in the study. Linked claims analyses found that patients with novel and canonical ALK or FGFR2 fusions who received matched tyrosine kinase inhibitors had comparable survival, and both groups had longer survival than patients who received non-tyrosine kinase inhibitor treatments.

In the gynecologic cancer study, PAK1, PAK2, or PAK3 fusions were identified in 237 tumors, representing 0.17% of ovarian, fallopian tube, and primary peritoneal serous carcinoma tumors studied. The fusions involved a range of gene partners, with DLG1 and GAB2 reported as the most common. The findings showed that these rare fusions appeared in both high-grade and borderline or low-grade serous carcinomas.

“Gene fusions can be important drivers of cancer, but identifying the full spectrum of these alterations requires a comprehensive view of the tumor. By applying WTS across a dataset of this scale, we can uncover new and rare fusions, better understand their clinical significance and generate insights that can help advance precision oncology,” said George W. Sledge, Jr., MD, EVP and Chief Medical Officer at Caris.

Related Links
Caris Life Sciences


Latest Molecular Diagnostics News